Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dual small interfering RNA targeting WEE1 and PKMYT1
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Localized
01
Overview
A dual small interfering RNA (siRNA) therapeutic designed to simultaneously silence the WEE1 and PKMYT1 kinases. These kinases are key regulators of the G2/M cell cycle checkpoint, and their combined inhibition is intended to exploit synthetic lethal vulnerabilities in cancers like diffuse pleural mesothelioma (DPM). By knocking down both targets, the drug induces significant G2/M arrest, depletion of S-phase cells, and robust apoptosis. The therapeutic is formulated within a nanoparticle-hydrogel platform for localized delivery directly to the tumor site, minimizing systemic toxicity while maximizing efficacy at the disease interface.
- Other names
- WEE1/PKMYT1 dual-siRNAdual-siRNA targeting WEE1 and PKMYT1
02
Targets
PKMYT1 (Protein kinase membrane associated tyrosine/threonine 1)WEE1 (WEE1 G2 checkpoint kinase)
Beyond the preview
Go deeper on dual small interfering RNA targeting WEE1 and PKMYT1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dual small interfering RNA targeting WEE1 and PKMYT1.